12/1
06:00 pm
mnov
Message from the CEO to MediciNova Shareholders
Low
Report
Message from the CEO to MediciNova Shareholders
11/25
01:54 pm
mnov
MediciNova (NASDAQ:MNOV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
MediciNova (NASDAQ:MNOV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
06:57 am
mnov
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor [Yahoo! Finance]
Neutral
Report
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor [Yahoo! Finance]
11/18
06:00 am
mnov
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
Low
Report
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
11/7
01:14 am
mnov
MediciNova (NASDAQ:MNOV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
MediciNova (NASDAQ:MNOV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/6
06:55 pm
mnov
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards [Yahoo! Finance]
Low
Report
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards [Yahoo! Finance]
11/6
06:00 pm
mnov
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
High
Report
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
11/4
07:00 am
mnov
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
Low
Report
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
10/31
09:00 pm
mnov
MediciNova compounds demonstrate novel therapeutic approach for Atherosclerosis [Yahoo! Finance]
Low
Report
MediciNova compounds demonstrate novel therapeutic approach for Atherosclerosis [Yahoo! Finance]
10/31
08:06 am
mnov
MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
High
Report
MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
10/30
07:09 pm
mnov
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication [Yahoo! Finance]
Medium
Report
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication [Yahoo! Finance]
10/30
07:00 pm
mnov
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
High
Report
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
10/6
08:00 am
mnov
MediciNova to Present at the LD Micro Main Event XIX Investor Conference
Medium
Report
MediciNova to Present at the LD Micro Main Event XIX Investor Conference
9/23
07:38 am
mnov
MediciNova concludes subject enrolment in trial of MN-166 [Yahoo! Finance]
Low
Report
MediciNova concludes subject enrolment in trial of MN-166 [Yahoo! Finance]
9/22
11:03 am
mnov
MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
Low
Report
MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
9/22
08:19 am
mnov
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast) [Yahoo! Finance]
Low
Report
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast) [Yahoo! Finance]
9/22
08:00 am
mnov
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
Low
Report
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
9/16
08:00 am
mnov
MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
Low
Report
MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
9/13
05:50 am
mnov
MediciNova (NASDAQ:MNOV) was upgraded by analysts at Zacks Research to a "hold" rating.
Low
Report
MediciNova (NASDAQ:MNOV) was upgraded by analysts at Zacks Research to a "hold" rating.
9/8
09:35 am
mnov
MediciNova Provides Shareholder Update on Key Developments [Yahoo! Finance]
Low
Report
MediciNova Provides Shareholder Update on Key Developments [Yahoo! Finance]
9/8
09:00 am
mnov
MediciNova Provides Shareholder Update on Key Developments
Low
Report
MediciNova Provides Shareholder Update on Key Developments